150,000 Shares in Bruker Co. (NASDAQ:BRKR) Purchased by Intrinsic Edge Capital Management LLC

Intrinsic Edge Capital Management LLC purchased a new stake in Bruker Co. (NASDAQ:BRKR - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 150,000 shares of the medical research company's stock, valued at approximately $8,793,000. Intrinsic Edge Capital Management LLC owned about 0.10% of Bruker as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC grew its position in Bruker by 1.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company's stock valued at $779,000 after acquiring an additional 177 shares during the period. Quadrant Capital Group LLC raised its holdings in shares of Bruker by 18.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after buying an additional 196 shares during the period. Insigneo Advisory Services LLC boosted its holdings in Bruker by 4.7% in the 4th quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company's stock worth $286,000 after acquiring an additional 218 shares during the period. Arizona State Retirement System grew its position in Bruker by 0.7% in the fourth quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company's stock valued at $1,801,000 after acquiring an additional 222 shares in the last quarter. Finally, CIBC Asset Management Inc raised its stake in shares of Bruker by 5.6% during the fourth quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company's stock valued at $248,000 after purchasing an additional 223 shares during the period. Hedge funds and other institutional investors own 79.52% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Citigroup cut their price target on Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. Stifel Nicolaus reduced their price objective on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research note on Friday, February 14th. Guggenheim reiterated a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Barclays reduced their target price on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Finally, Wells Fargo & Company dropped their price target on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research report on Thursday, April 17th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $65.00.

Bruker Stock Performance

Shares of BRKR stock traded down $0.40 during trading hours on Thursday, reaching $39.66. The stock had a trading volume of 517,444 shares, compared to its average volume of 1,522,274. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The firm has a 50-day simple moving average of $42.51 and a 200-day simple moving average of $52.27. The firm has a market capitalization of $6.01 billion, a PE ratio of 52.10, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker Co. has a twelve month low of $34.10 and a twelve month high of $80.02.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, equities analysts forecast that Bruker Co. will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date of this dividend was Monday, March 17th. Bruker's dividend payout ratio is currently 26.32%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.